beta

CLRB

Cellectar BioSciences, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Market Cap: 10.7 Million

Primary Exchange: NASDAQ

Website: http://www.cellectar.com

Shares Outstanding: 9.4 Million

Float: 8.16 Million

Dividend: (%)

Beta: 0.735141767812181

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 1544 trading days

From: 2014-06-24 To: 2020-06-04

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2016-03-07 10.0 1.0 10.0
Data provided by IEX Cloud